/* mobile /* end mobile MEDDESKTOP: Eli Lilly Terminates the AIR® Inhaled Insulin (AIR® Insulin) program With Alkermes

Sunday, March 09, 2008

Eli Lilly Terminates the AIR® Inhaled Insulin (AIR® Insulin) program With Alkermes

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alkermes, Inc. (NASDAQ: ALKS) announced that it has received a letter terminating the development and license agreement between Eli Lilly and Company (Lilly) and Alkermes dated April 1, 2001 thereby terminating the AIR® Inhaled Insulin (AIR® Insulin) program. The termination will become effective in 90 days. The termination of the agreement also results in the termination of the AIR Insulin supply agreement.

Alkermes is evaluating the impact of the termination of the AIR Insulin program on its business and will provide further details following a comprehensive business analysis.

tag: , , , ,

No comments:

LinkWithin

Related Posts Widget for Blogs by LinkWithin